Hims & Hers Health Inc SEC Filings

Insider sale by HIMS officer: The Form 4 shows Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), sold 2,571 shares of Class A common stock on 08/25/2025 at a price of $44.53 per share. After the reported sale, Boughton beneficially owned 150,450 shares. The filing was signed by an attorney-in-fact on 08/26/2025 and indicates the sale was executed under the reporting person’s authority.

Form 144 filed relating to HIMS (HIMS): The notice reports a proposed sale of 2,571 Class A shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $114,486.63 and an approximate sale date of 08/25/2025. The shares were acquired on 06/15/2025 by Restricted Stock Vesting from the issuer and were paid as compensation. The filing lists multiple prior Class A sales by Soleil Boughton between 05/27/2025 and 08/11/2025, showing amounts and gross proceeds for each trade. Some issuer and filer identifying fields in the header are blank or not provided in the document.

Andrew Dudum, Director and CEO of Hims & Hers Health, Inc. (HIMS), reported multiple transactions on 08/18/2025 conducted under a Rule 10b5-1 plan. The filing shows option exercises at an exercise price of $2.43 for 17,001 and 108,334 options, and subsequent sales of shares from those exercises and existing holdings at average weighted prices in the mid-$44 to mid-$45 range. Reported sales on that date include blocks of 47,534; 2,792; 17,001; 41,667; 50,000; and 16,667 shares at various average prices around $44.76–$45.42. Post-transaction beneficial ownership across direct and indirect holdings is reported for numerous trusts, with notable indirect positions such as 1,016,871 and 2,214,769 shares held by trustees. The Form 4 is signed by an attorney-in-fact on 08/20/2025.

Form 144 notice for Hims & Hers Health, Inc. (HIMS) reports proposed and recent sales of Class A common stock by insiders and related parties. The filing lists a proposed sale of 47,534 shares via Fidelity (approximate market value $2,141,494) with an approximate sale date of 08/18/2025 on the NYSE. It shows acquisition details for 46,534 vested restricted shares received in 2022 and 2023 as compensation. The filing also discloses multiple completed insider sales between 06/16/2025 and 07/21/2025 totaling several hundred thousand shares and gross proceeds in the multi‑million dollar range. The filer certifies they are not aware of undisclosed material adverse information.

Form 144 notice for HIMS (Class A) shows a proposed sale of 128,127 Class A shares with an aggregate market value of $5,793,902.94, scheduled approximately for 08/18/2025. The filing reports that 125,335 of those shares derive from an option granted on 06/17/2020 and are to be sold for cash on 08/18/2025, while 2,792 shares were acquired by restricted stock vesting on 06/15/2024 as compensation. The issuer's outstanding Class A shares are reported as 217,641,958. The filing also discloses multiple Class A sales by Andrew Dudum and the Dudum Family Trust between 06/16/2025 and 07/21/2025 with detailed gross proceeds for each transaction.

Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), reported transactions on 08/13/2025. The filing shows acquisition of 11,581 shares at an exercise price of $5.01 and a contemporaneous sale of 11,581 shares at a weighted average price of $48.0459, with sales executed in the range $47.84–$48.32. The report also records a transfer of 62,722 Class A shares from the Oluyemi Okupe Separate Property Trust dated 9-1-2021 to the reporting person’s direct holdings. Post-transaction direct beneficial ownership is reported as 65,665 Class A shares. The exercised options referenced vest per a schedule beginning January 24, 2023, with full monthly vesting thereafter and expire February 23, 2032.

Andrew Dudum, Chief Executive Officer and director of Hims & Hers Health, Inc., reports beneficial ownership equal to 23,820,905 shares of Class A common stock on a fully converted/exercised basis, representing 10.3% of Class A. That total combines shares held directly and in affiliated trusts, Class V common stock that converts into Class A, restricted stock units expected to settle within 60 days, and a large block of stock options exercisable within 60 days.

The filing breaks down the holdings: 9,333,039 Class A shares held by affiliated trusts, 92,313 held directly, 8,377,623 Class V shares, 164,368 Class A shares underlying RSUs expected to settle within 60 days, 5,643,186 options exercisable within 60 days, plus additional options and RSUs subject to vesting; 1,296,568 RSUs not expected to settle within 60 days are excluded from the aggregate amount. The filing also notes that Class V shares convert into Class A upon transfer or by Board resolution after specified trigger conditions.